Insights
Search Results
Client Highlights
10.07.24
Firm Advises Ahren, OMX Ventures, +ND Capital, and Fine Structures Ventures on Constructive Bio’s $58 Million Series A
On September 24, 2024, Constructive Bio, a pioneering synthetic genomics company, announced that it has secured $58 million in the first close of its Series A financing, bringing the total amount raised by the company to date to $75 million. The round was led by Ahren Innovation Capital, OMX Ventures, and Paladin Capital Group with participation from Fine Structure Ventures, +ND Capital, and Abcam-founder Jonathan Milner. Wilson Sonsini Goodrich & Rosati advised Ahren, OMX Ventures, +ND Capital, and Fine Structures Ventures on the transaction.
Client Highlights
2.22.24
Wilson Sonsini Advises Prime Medicine on IP Matters Related to Upsized Public Offering
On February 20, 2024, Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced the closing of its underwritten upsized public offering of 22,560,001 shares of its common stock. Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the transaction.
The upsized public offering includes the full exercise of the underwriters’ option to purchase 3,360,000 additional shares of its common stock, at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
The Wilson Sonsini team that advised Prime Medicine on IP matters related to the transaction included Lou Lieto, Clark Lin, Rachna Ujwal, Esther Cynn, and David Stanton.
For more information please see Prime Medicine’s press release.
The upsized public offering includes the full exercise of the underwriters’ option to purchase 3,360,000 additional shares of its common stock, at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
The Wilson Sonsini team that advised Prime Medicine on IP matters related to the transaction included Lou Lieto, Clark Lin, Rachna Ujwal, Esther Cynn, and David Stanton.
For more information please see Prime Medicine’s press release.
Client Highlights
11.14.23
Wilson Sonsini Advises CARGO Therapeutics on IP Matters Related to $281 Million IPO
On November 10, 2023, CARGO Therapeutics, a clinical-stage biotech specializing in cancer treatments, made its debut on the Nasdaq Global Select Market under the ticker "CRGX" after successfully raising approximately $281 million through its initial public offering (IPO). The company priced its IPO at $15 per share, issuing 18.75 million shares. Wilson Sonsini Goodrich & Rosati advised CARGO on patent and technology transactions matters leading up to and with respect to the IPO.
Client Highlights
3.02.23
Wilson Sonsini Advises CARGO Therapeutics on Series A Financing
On March 1, 2023, CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, announced the close of a $200 million oversubscribed and upsized Series A financing. The financing was co-led by Third Rock Ventures, RTW Investments, LP, and Perceptive Xontogeny Venture Fund, and includes additional new investors Nextech, Janus Henderson Investors, Ally Bridge Group, Wellington Management, funds and accounts advised by T. Rowe Price Associates, Inc., Cormorant Asset Management, and Piper Heartland. Founding investor Samsara BioCapital and existing seed investors Red Tree Venture Capital and Emerson Collective also participated in the financing.
Client Highlights
10.20.22
Wilson Sonsini Advises Prime Medicine on Patent Matters Related to $175 Million IPO
On October 19, 2022, Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced the pricing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share. The shares began trading on the Nasdaq Global Market on October 20 under the ticker symbol “PRME.” Wilson Sonsini Goodrich & Rosati is advising Prime Medicine on all patent matters related to the transaction.
The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prime Medicine, are expected to be $175.0 million. In addition, the underwriters have a 30-day option to purchase up to 1,544,117 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prime Medicine, are expected to be $175.0 million. In addition, the underwriters have a 30-day option to purchase up to 1,544,117 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.